[41] demonstrated through clinical studies on FSGS patients and in vitro and in vivo experiments that miR-30s protected podocytes by targeting NOTCH1 and P53, and the downregulation of miR-30s led to enhanced signal transduction of NOTCH1 and P53, leading to podocyte damage. This evidence concerns the gene TP53 and focal segmental glomerulosclerosis.